News | July 22, 2024
dsm-firmenich to sell MEG-3 fish oil business to KD Pharma Group
dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business
dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business
The facility will manufacture tablets, capsules, and injections for the oncology segment
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
This investment will be made by Caplin Point Laboratories Limited and its subsidiaries - Caplin Steriles Limited and Caplin One Labs Limited
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Bains has stepped down from his role on the Biocon Board as an Independent Director with immediate effect
Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base
Subscribe To Our Newsletter & Stay Updated
